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1. INTRODUCTION {#apl13913-sec-0005}
===============

Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), was declared a pandemic by the World Health Organization (WHO) on 11 March 2020. As at 24 May 2020 there have been 7135 cases of COVID‐19 confirmed in Australia, of which 947 (13%) have been hospitalized, 202 (21%) required intensive care unit (ICU) admission and 102 have died.[^1^](#apl13913-bib-0001){ref-type="ref"}

Twenty percent of COVID‐19 cases can develop acute respiratory distress syndrome (ARDS), which confers up to 62% mortality.[^2^](#apl13913-bib-0002){ref-type="ref"}, [^3^](#apl13913-bib-0003){ref-type="ref"} Despite low rates of severe disease in Australia,[^4^](#apl13913-bib-0004){ref-type="ref"} therapies for COVID‐elated ARDS are urgently needed.

There is emerging evidence that COVID‐19‐related ARDS is triggered by excessive secretion of pro‐inflammatory signaling molecules, termed cytokine release syndrome (CRS).[^2^](#apl13913-bib-0002){ref-type="ref"} While there is no consensus definition of COVID‐19 CRS, current data suggest it is clinically characterized by rapid‐onset respiratory failure and biochemically characterized by raised interleukin‐6 (IL‐6) and its surrogate markers, including C‐reactive protein (CRP) and ferritin.[^5^](#apl13913-bib-0005){ref-type="ref"}, [^6^](#apl13913-bib-0006){ref-type="ref"}

Tocilizumab, a humanized monoclonal antibody targeting the IL‐6 receptor (IL‐6R), was approved by the Therapeutic Goods Administration for the treatment of rheumatoid arthritis in Australia in 2009.[^7^](#apl13913-bib-0007){ref-type="ref"} Established uses have since expanded to include juvenile idiopathic arthritis (JIA), giant cell arteritis, chimeric antigen receptor (CAR) T‐cell therapy CRS and secondary hemophagocytic lymphohistiocytosis (sHLH) related to JIA, also termed macrophage activation syndrome.[^8^](#apl13913-bib-0008){ref-type="ref"} Although tocilizumab is generally well tolerated in patients with rheumatic diseases, serious infections are reported at a rate of 4.7 events per 100 patient‐years of use, including bacterial, viral and opportunistic infections, some of which have been fatal.[^7^](#apl13913-bib-0007){ref-type="ref"} Tocilizumab is relatively contraindicated in patients with active infection.[^7^](#apl13913-bib-0007){ref-type="ref"}, [^9^](#apl13913-bib-0009){ref-type="ref"}

Some clinical and laboratory findings in COVID‐19 CRS are similar to those found in sHLH and CRS induced by CAR T‐cell therapy.[^2^](#apl13913-bib-0002){ref-type="ref"}, [^10^](#apl13913-bib-0010){ref-type="ref"} However, it is not yet known whether IL‐6, which is implicated as causative in the latter two conditions[^2^](#apl13913-bib-0002){ref-type="ref"}, [^11^](#apl13913-bib-0011){ref-type="ref"} plays a similar role in COVID‐19 CRS.[^8^](#apl13913-bib-0008){ref-type="ref"}, [^11^](#apl13913-bib-0011){ref-type="ref"} IL‐6 is also raised in severe sepsis,[^12^](#apl13913-bib-0012){ref-type="ref"} but data related to tocilizumab in sepsis are limited to in vitro and animal studies, and other immune interventions in sepsis using tumor necrosis factor alpha and interleukin‐1 antagonists have not been associated with improved outcomes.[^13^](#apl13913-bib-0013){ref-type="ref"}, [^14^](#apl13913-bib-0014){ref-type="ref"}

Following the publication of two small, uncontrolled, retrospective case series from China,[^15^](#apl13913-bib-0015){ref-type="ref"} there has been considerable interest in tocilizumab use in patients with COVID‐19.[^2^](#apl13913-bib-0002){ref-type="ref"}, [^10^](#apl13913-bib-0010){ref-type="ref"}, [^16^](#apl13913-bib-0016){ref-type="ref"} Two case control series reporting positive short‐term outcomes have now been published in the peer‐reviewed scientific literature,[^17^](#apl13913-bib-0017){ref-type="ref"}, [^18^](#apl13913-bib-0018){ref-type="ref"} and two additional case control series have been published to the preprint server *medRxiv* but are yet to undergo peer review.[^19^](#apl13913-bib-0019){ref-type="ref"}, [^20^](#apl13913-bib-0020){ref-type="ref"} We describe our experience using tocilizumab in patients with severe COVID‐19 pneumonia.

2. MATERIALS AND METHODS {#apl13913-sec-0006}
========================

Between 30 March 2020 and 11 April 2020, 5 patients with clinical deterioration in the context of a systemic inflammatory response to COVID‐19 were treated with tocilizumab at three tertiary referral hospitals, 2 in NSW and 1 in Victoria. All patients had confirmed SARS‐CoV2 infection based on real‐time polymerase chain reaction analysis of nasal swab sample, radiological findings consistent with COVID‐19 pneumonia and biochemical evidence of systemic inflammation with CRP greater than 100 mg/L (NR \[normal range\] ≤5 mg/L) and ferritin greater than 700 μg/L (NR 30‐400 μg/L). At the time of tocilizumab administration, three patients met the Berlin ARDS definition,[^21^](#apl13913-bib-0021){ref-type="ref"} had undergone endotracheal intubation and were mechanically ventilated due to type 1 respiratory failure. The other 2 patients had rapid, progressive type 1 respiratory failure but did not meet the Berlin ARDS definition as continuous positive airway pressure was not applied due to concern for aerosolization of SARS‐CoV2. The decision to treat with tocilizumab was made by consensus between the involved intensive care, respiratory, infectious diseases and immunology specialists. Informed consent was obtained from the patient in two cases and from the next of kin in the three intubated patients. Clinical information for each patient was obtained from a review of electronic and paper medical record systems, from which sequential organ failure assessment (SOFA) score[^22^](#apl13913-bib-0022){ref-type="ref"} and H‐score[^23^](#apl13913-bib-0023){ref-type="ref"} were calculated where possible. Ethics approval was not required at two sites and was obtained at one site. All patients consented to publication.

3. RESULTS {#apl13913-sec-0007}
==========

The five patients were aged between 46 and 74 years and were followed for between 13 and 26 days after tocilizumab therapy; see Figure [1](#apl13913-fig-0001){ref-type="fig"}. Table [1](#apl13913-tbl-0001){ref-type="table"} describes patient demographics, past medical history and time‐course of events prior to tocilizumab administration. All patients additionally received broad‐spectrum antibiotics; four patients received corticosteroids; and two received both hydroxychloroquine and lopinavir/ritonavir (LPV/r). The time from tocilizumab administration to improvement in oxygenation, defined as a 25% fall in fraction of inspired oxygen (FiO2) required to maintain peripheral oxygen saturation (SpO2) greater than 92%, ranged from 7 hours to 4.6 days; Table [2](#apl13913-tbl-0002){ref-type="table"} describes tocilizumab dose, additional medications administered, progress following treatment and adverse events. Table [3](#apl13913-tbl-0003){ref-type="table"} and Figure [2](#apl13913-fig-0002){ref-type="fig"} describe clinical and laboratory results before and after tocilizumab treatment, and in Table [S1](#apl13913-sup-0001){ref-type="supplementary-material"} the Supplementary Appendix details further laboratory parameters.

![Timeline of clinical progress of COVID‐19 patients before and after tocilizumab treatment. COVID‐19, coronavirus disease 2019; ICU, intensive care unit; L/min, liters per minute; TCZ, tocilizumab](APL-23-1030-g001){#apl13913-fig-0001}

###### 

Patient background, time‐course of admission and assessment prior to tocilizumab administration

                                            Patient 1                    Patient 2                                                                  Patient 3                                                 Patient 4                   Patient 5
  ----------------------------------------- ---------------------------- -------------------------------------------------------------------------- --------------------------------------------------------- --------------------------- ----------------------
  Demographic data and medical background                                                                                                                                                                                                 
  Age (y)                                   53                           74                                                                         71                                                        70                          46
  Gender                                    Male                         Male                                                                       Male                                                      Male                        Male
  Weight (kg)                               70                           90                                                                         68                                                        72                          86
  BMI (kg/m^2^)                             25.1                         27.2                                                                       23.0                                                      26.5                        32.8
  Smoker                                    No                           No                                                                         No                                                        No                          No
  Ethnicity                                 Chinese                      Caucasian                                                                  Caucasian                                                 Indian                      Filipino
  Coexisting chronic diseases               Hypertension, dyslipidemia   Type II diabetes mellitus, hypertension                                    Dyslipidemia, aortic valve replacement, lacunar stroke    Type II diabetes mellitus   Asthma, obesity
  Regular medications                       Rosuvastatin, telmisartan    Allopurinol, aspirin, gliclazide MR, irbesartan, metformin, rosuvastatin   Aspirin, pantoprazole, ramipril, rosuvastatin, warfarin   Metformin                   Salbutamol as‐needed
  Time‐course from day of symptom onset                                                                                                                                                                                                   
  Event                                     Days later                   Days later                                                                 Days later                                                Days later                  Days later
  SARS‐CoV2 swab + ve                       2                            3                                                                          1                                                         2                           0
  Hospital admission                        11                           6                                                                          13                                                        2                           3
  O2 requirement started                    11                           9                                                                          13                                                        3                           5
  ICU admission                             11                           14                                                                         13                                                        3                           6
  Intubation                                11                           (Not intubated)                                                            (Not intubated)                                           3                           7
  TCZ administration                        11                           14                                                                         13                                                        9                           9
  Assessment prior to TCZ                                                                                                                                                                                                                 
  PF ratio (mm Hg)                          124                          198                                                                        93                                                        112                         69
  SOFA score                                6                            2                                                                          2                                                         7                           14
  H‐score                                   Insufficient data            Insufficient data                                                          Insufficient data                                         151                         132
  Infection screen                                                                                                                                                                                                                        
  When tested vs TCZ                        4 d prior                    2 h after                                                                  3 h prior                                                 11 h prior                  Not tested
  QuantiFERON Gold                          Indeterminate                Indeterminate                                                              Indeterminate                                             Not tested                  Not tested
  Hepatitis B serology                      Vaccinated                   Negative                                                                   Negative                                                  Negative                    Not tested
  HIV serology                              Negative                     Negative                                                                   Negative                                                  Negative                    Not tested

Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; ICU, intensive care unit; MR, modified release; O2, oxygen; PF ratio, ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen; SARS‐CoV2, severe acute respiratory syndrome‐coronavirus 2; SOFA, sequential organ failure assessment; TCZ, tocilizumab.
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###### 

Tocilizumab treatment, other treatments received and response to tocilizumab administration

             Patient 1            Patient 2            Patient 3                       Patient 4                        Patient 5
  ---------- -------------------- -------------------- ------------------------------- -------------------------------- --------------------
  TCZ dose   400 mg IV x 1 dose   800 mg IV x 1 dose   400 mg IV x 2 doses 8 h apart   600 mg IV x 2 doses 39 h apart   800 mg x IV 1 dose

  Medication                  Dose and duration                             Dose and duration                                   Dose and duration                             Dose and duration                                                      Dose and duration
  --------------------------- --------------------------------------------- --------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------
  Other treatments received                                                                                                                                                                                                                          
  Corticosteroids             MP 1 mg/kg IV daily x 2 doses from d of TCZ   P 25 mg/d tapered to cessation from 5 d after TCZ   No                                            P 25 mg/d x 3 d then 75 mg/d x 3 d finishing on d of hospitalization   MP 1 g x 1 dose, 100 mg/d x 3 d, 40 mg x 3 d, 5 mg x 1 d from d of TCZ
  Antiretrovirals             LPV/r 400 mg/ 100 mg BD x 6 d from d of TCZ   No                                                  LPV/r 400 mg/ 100 mg BD x 3 d from d of TCZ   No                                                                     No
  Antimalarial                HCQ 200 mg BD x 6 d from d of TCZ             No                                                  HCQ 200 mg BD x 6 d from d of TCZ             No                                                                     No

  Event                                         Days later   Days later        Days later         Days later         Days later
  --------------------------------------------- ------------ ----------------- ------------------ ------------------ ------------------
  Timing from d of TCZ to key clinical events                                                                        
  Extubation                                    4            (Not intubated)   (Not intubated)    17                 12
  ICU discharge                                 5            1                 6                  24                 14
  O2 therapy cessation                          6            7                 Not yet achieved   Not yet achieved   14
  Hospital discharge                            10           13                Not yet achieved   Not yet achieved   Not yet achieved
  Final day of follow‐up                        25           13                19                 26                 24

  Criterion                        Time vs TCZ                        Time vs TCZ        Time vs TCZ    Time vs TCZ   Time vs TCZ
  -------------------------------- ---------------------------------- ------------------ -------------- ------------- -------------------------------------------------------------------------------------------------
  Response to TCZ administration                                                                                      
  Defervescence (fever \< 38°C)    Immediate                          3 d prior to TCZ   Immediate      Immediate     5 h
  FiO2 fall \> 25%                 4.6 d                              15 h               50 h           4.0 d         7 h
  CRP fall \> 25%                  37 h                               46 h               35 h           18 h          31 h
  CRP fall \> 50%                  37 h                               46 h               35 h           41 h          31 h
  Ferritin fall \> 25%             62 h                               22 h               Not achieved   41 h          55 h
  Ferritin fall \> 50%             Not achieved                       Not achieved       Not achieved   17.6 d        10.3 d
  Radiographic improvement         41 h                               9.8 d              10.2 d         7.1 d         3.3 d
  Adverse event**s**               Ventilator‐associated pneumonia.   Nil.               Hepatitis.     Delirium.     Renal failure, myositis, line‐associated *Staphylococcus epidermidis* bacteremia, eosinophilia.

Abbreviations: BD, twice daily; CRP, C‐reactive protein; FiO2, fraction of inspired oxygen; HCQ, hydroxychloroquine; ICU, intensive care unit; IV, intravenous; LPV/r, oral lopinavir/ritonavir; MP, intravenous methylprednisolone; O2, oxygen; P, oral prednisolone; PO, per oral; TCZ, tocilizumab.
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###### 

Clinical and laboratory parameters of COVID‐19 patients before and after TZC treatment

  Case No.                      Before TCZ therapy   Day of TCZ therapy   Days after TCZ therapy   Clinical outcome                                                       
  ----------------------------- -------------------- -------------------- ------------------------ ------------------ ------ ------ ------ ----- ------ ----- ----- ----- ----------------------------------------------------------------------------------------
  Ventilation and oxygenation                                                                                                                                             
  1                             Time vs TCZ          2 d prior            Same day                                                                                        Discharged home d 10 post‐TCZ.
  O2 delivery method            ETT                  ETT                  ETT                      ETT                ETT    NP     NP     NP    RA     RA    RA          
  FiO2 (%)                      80                   30                   30                       30                 35     36     36     28    21     21    21          
  PF ratio (mm Hg)              124                  253                  253                      253                209    226    306    286                            
  2                             Time vs TCZ          8 d prior            Same day                                                                                        Discharged home d 13 post‐TCZ.
  O2 delivery method            RA                   HM                   HM                       NP                 NP     NP     NP     NP    NP     NP    RA          
  FiO2 (%)                      21                   60                   60                       36                 36     36     36     32    28     28    21          
  PF ratio (mm Hg)                                   198                  198                      277                                                                    
  3                             Time vs TCZ          Same day             Same day                                                                                        D 19 post‐TCZ: remains in hospital on ward bed on oxygen 2 L/min.
  O2 delivery method            HM                   HM                   HM                       NP                 NP     NP     NP     NP    NP     NP    NP          
  FiO2 (%)                      60                   60                   60                       36                 36     36     36     36    36     36    28          
  PF ratio (mm Hg)              93                   93                   93                       277                                                                    
  4                             Time vs TCZ          7 d prior            6 d prior                                                                                       D 26 post‐TCZ: remains in hospital on ward bed on oxygen 2 L/min.
  O2 delivery method            RA                   ETT                  ETT                      ETT                ETT    ETT    ETT    ETT   ETT    ETT   ETT         
  FiO2 (%)                      21                   45                   55                       60                 70     60     40     40    30     40    40          
  PF ratio (mm Hg)              342                                       112                      97                 81     95     165    135   186    140   165         
  5                             Time vs TCZ          6 d prior            2 d prior                                                                                       D 24 post‐TCZ: remains in hospital on ward bed, breathing room air, on renal dialysis.
  O2 delivery method            RA                   HM                   ETT                      ETT                ETT    ETT    ETT    ETT   ETT    ETT   ETT         
  FiO2 (%)                      RA                   30                   100                      45                 50     35     35     35    30     35    30          
  PF ratio (mm Hg)                                   183                  69                       193                128    314    197    171   213    200   267         
  CRP (mg/L; NR ≤ 4.9)                                                                                                                                                    
  1                                                  227                  236                      236                216    86     33     16           4     3           
  2                                                  82                   128                      128                       37     17     12    9      6                 
  3                                                  269                  269                      269                236    86     40     21    11     7           2     
  4                                                  91                   226                      530                389    164    73     40    24     17    17    12    
  5                                                  87                   105                      312                319    177    89           23           6     3     
  Ferritin (μg/L; NR 30‐400)                                                                                                                                              
  1                                                  4700                 4396                     4396               4501   2684                2670                     
  2                                                  259                  738                      738                545    470    379    457   420    420               
  3                                                  731                  731                      731                774    865    812    762   681    669         546   
  4                                                                                                3177                      2666   2296                                  
  5                                                                                                2080               2074   1611   1501                                  
  LDH (U/L; NR ≤ 250)                                                                                                                                                     
  1                                                  471                  362                      362                       466    288                 394               
  2                                                                       255                      255                213    221           227   231    202               
  3                                                  731                  731                      417                309    328    281    254   291    230         270   
  4                                                                                                324                       303    280                                   
  5                                                                                                705                              541                                   

Abbreviations: COVID‐19, coronavirus disease 2019; CRP, C‐reactive protein; ETT, endotracheal tube; FiO2, fraction of inspired oxygen; HM, Hudson mask; ICU, intensive care; LDH, lactate dehydrogenase; NP, nasal prongs; NR, normal range; O2, oxygen; PF ratio, ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen; RA, room air; TCZ, tocilizumab; U/L, units per liter.
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![Clinical and laboratory parameters of COVID‐19 patients before and after TCZ treatment. COVID‐19, coronavirus disease 2019; TCZ, tocilizumab](APL-23-1030-g002){#apl13913-fig-0002}

3.1. Patient 1 {#apl13913-sec-0008}
--------------

A 53‐year‐old man with a history of hypertension presented to hospital with fever and rapid‐onset type I respiratory failure due to COVID‐19 pneumonia. At presentation, partial pressure of oxygen in arterial blood (PaO2) was 99 mm Hg while receiving FiO2 80% yielding PaO2 to FiO2 ratio (PF ratio) of 93 mm Hg. He underwent endotracheal intubation and was mechanically ventilated using the ARDSNet protocol[^24^](#apl13913-bib-0024){ref-type="ref"} to manage adequate gas exchange and noradrenaline to maintain mean arterial blood pressure greater than 70 mm Hg. A total of 6 days LPV/r and hydroxychloroquine were administered commencing at day 2 of hospitalization. On day 3 of hospitalization, intravenous (IV) tocilizumab 400 mg and methylprednisolone 70 mg (1 mg/kg) were administered. Noradrenaline was ceased 6 hours after tocilizumab administration. Two days after tocilizumab therapy, ventilatory function improved, but signs of encephalopathy arose when sedation was weaned. Corticosteroids were therefore ceased and encephalopathy resolved rapidly. Ventilator‐associated pneumonia, diagnosed 3 days after tocilizumab administration, was treated with piperacillin/tazobactam. Three days following tocilizumab administration, the patient was extubated. He was discharged from ICU 5 days after tocilizumab administration, ceased oxygen therapy 1 day later, and was discharged home after a further 4 days.

3.2. Patient 2 {#apl13913-sec-0009}
--------------

A 74‐year‐old man with a history of type II diabetes and hypertension presented to hospital with COVID‐19 pneumonia, with SpO2 95% on room air at presentation. He became hypoxic on admission day 3, and oxygen therapy, ceftriaxone and azithromycin were commenced. On day admission 9 he developed rapid‐onset type I respiratory failure with clinical and biochemical features of COVID‐19 CRS. PaO2 was 119 mm Hg while receiving oxygen 8 L/min via Hudson mask (estimated FiO2 60%) yielding a PF ratio of 198 mm Hg. He was admitted to ICU and tocilizumab 800 mg IV was administered. Following tocilizumab administration, estimated FiO2 requirement fell from 60% to 36% in 16 hours while maintaining SpO2 greater than 92%. He did not require endotracheal intubation. He was discharged from ICU 20 hours after tocilizumab administration. He then remained stable on FiO2 36% for 5 days, when oral prednisone 25 mg daily was commenced. Oxygen therapy was ceased 7 days after tocilizumab administration, and he was discharged home 6 days later. Corticosteroids were tapered to cessation over 2 weeks.

3.3. Patient 3 {#apl13913-sec-0010}
--------------

A 71‐year‐old man with a history of bioprosthetic aortic valve replacement and lacunar stroke presented to hospital with fever and acute type I respiratory failure due to COVID‐19 pneumonia. PaO2 was 56 mm Hg while receiving oxygen 8 L/min via Hudson mask (estimated FiO2 60%) yielding a PF ratio of 93 mm Hg. He was immediately admitted to ICU and 2 doses of 400 mg tocilizumab were administered 8 hours apart. FiO2 requirement reduced to 36% while maintaining SpO2 greater than 92% 50 hours after first tocilizumab administration. He did not require endotracheal intubation and complied with conscious proning for 16 hours per day. He received 3 days of LPV/r and 6 days of hydroxychloroquine; all were ceased due to prolonged corrected QT interval on electrocardiogram. He was discharged from ICU 6 days after tocilizumab administration. Twelve days after tocilizumab administration he developed hepatitis, which resolved over 5 days without specific intervention. A screen for infectious and autoimmune hepatitis was negative. Abdominal ultrasound demonstrated hepatic steatosis. Gastroenterology opinion was of either drug‐induced liver injury or COVID‐19 hepatitis. On day 19 after tocilizumab administration he remained admitted to hospital, requiring oxygen via nasal cannulae.

3.4. Patient 4 {#apl13913-sec-0011}
--------------

A 70‐year‐old man with a history of recently diagnosed type II diabetes presented to hospital with acute type I respiratory failure due to COVID‐19 pneumonia, with PF ratio of 343 mm Hg and CRP of 91 mg/L at hospital admission. Intravenous ceftriaxone and azithromycin were commenced. On day 2 of hospitalization, he was admitted to ICU, underwent endotracheal intubation and commenced mechanical ventilation. Noradrenaline was administered to maintain mean airway pressure \>70 mm Hg. By admission day 7, PF ratio was 112 mm Hg and CRP was 530 mg/L. Starting on admission day 7, 2 doses of tocilizumab 600 mg (8 mg/kg) were administered 39 hours apart and IV piperacillin/tazobactam was commenced. Following tocilizumab dose 1, he remained critically unwell for 3 days. His PF ratio improved to 185 mm Hg on day 4 following the first dose of tocilizumab and noradrenaline was ceased 1 day later. Seventeen days after tocilizumab, his PF ratio was 303 mm Hg and he was extubated. Twenty‐four days after tocilizumab he was discharged from ICU, and on day 26 after tocilizumab administration he remained admitted to hospital, receiving oxygen via nasal cannulae. Fluctuating delirium has been his only complication.

3.5. Patient 5 {#apl13913-sec-0012}
--------------

A 46‐year‐old man with a history of obesity and asthma presented to hospital with COVID‐19 pneumonia, with SpO2 95% on room air at presentation. He developed type I respiratory failure on admission day 3 and underwent endotracheal intubation and mechanical ventilation on day 4. He developed acute kidney injury on admission day 5 requiring continuous renal replacement therapy by day 6. On day 6, PF ratio was 69 mm Hg and there were clinical and biochemical features of CRS. Manual proning was instituted, and a single dose of tocilizumab 800 mg IV and 1 g of IV methylprednisolone were administered, followed by IV methylprednisolone 100 mg daily for 3 days tapered to cessation over four further days. PF ratio improved to 193 mm Hg the day after tocilizumab administration, and he was extubated 11 days later. Oxygen therapy was ceased 15 days after tocilizumab administration.

His admission was complicated by myositis of uncertain etiology. Magnetic resonance imaging of the spine on day 17 post‐tocilizumab demonstrated extensive inflammation of the left psoas and iliacus muscles and surrounding the left lumbar plexus. He further suffered *Staphylococcus epidermidis* bacteremia attributed to central venous catheterization, treated with IV vancomycin and venous catheter removal, and developed an eosinophilia (peak 1.9 × 10⁹ cells/L) for which investigations are ongoing. At 24 days after tocilizumab administration, he remains admitted to hospital and dialysis‐dependent. Renal biopsy is being considered.

4. DISCUSSION {#apl13913-sec-0013}
=============

We present the first Australian cases of tocilizumab use in COVID‐19, comprising five patients with severe COVID‐19 pneumonia and clinical suspicion for CRS. Our retrospective, uncontrolled, open‐label, variable protocol, real‐world evidence series should be interpreted with caution. Nevertheless, we believe it is vital that such cases are published to inform current debate and to generate clinical hypotheses about mechanisms of disease and the potential for interventions.

At 13 to 26 days follow‐up of our five patients, 2 had been discharged home and 3 had left ICU but remained hospitalized. Three of 5 patients had ceased oxygen therapy. Where used, corticosteroids, LPV/r and hydroxychloroquine could have contributed to these outcomes. Further, there were several adverse events, including 1 with patient bacterial ventilator‐associated pneumonia, hepatitis, myositis and bacteremia attributed to central venous catheterization. Tocilizumab could be implicated in these events, but these findings are not uncommon in the critically ill and we await the results of randomized controlled trials to clarify the safety of tocilizumab in this population[^15^](#apl13913-bib-0015){ref-type="ref"}; LPV/r could also have contributed to hepatitis.

In the face of a rapidly expanding pandemic and when evidence‐based therapies or randomized trials of novel treatments are not available, it may be ethical to offer treatments with biologic plausibility and an established role in analogous diseases on a compassionate basis to patients in specific circumstances. For example, in the United States, both the Food and Drug Administration (FDA)[^25^](#apl13913-bib-0025){ref-type="ref"} and American Medical Association (AMA)[^25^](#apl13913-bib-0025){ref-type="ref"} state that compassionate use may be considered if: There is no comparable or satisfactory therapy available,the probable risk from the investigational product is not greater than the probable risk from the disease, andproviding the investigational product will not interfere with the conduct of clinical trials.

The significant mortality of severe COVID‐19 pneumonia provides further justification for administration of biologically plausible but unproven treatments within these parameters; this argument was also employed during the 2014‐2015 Ebola outbreak.[^26^](#apl13913-bib-0026){ref-type="ref"}

Of central importance is whether the inflammatory response to COVID‐19 is an adaptive response to severe infection, and when, if at all, pathogenic hyperinflammation occurs. Raised levels of IL‐6 have been shown to predict poor outcomes in severe COVID‐19 infection, and our data add to the published literature suggesting IL‐6 pathway inhibition may be beneficial.[^11^](#apl13913-bib-0011){ref-type="ref"} However, IL‐6 levels are also elevated in sepsis,[^12^](#apl13913-bib-0012){ref-type="ref"} where immune interventions have failed to show benefit.[^13^](#apl13913-bib-0013){ref-type="ref"} Further research into the immune response to SARS‐CoV2 infection is required.

Should Level 1 evidence for tocilizumab in COVID‐19 CRS emerge, patient selection and timing of drug administration will become crucial questions. Several protocols have been published, although none are backed by robust clinical data.[^27^](#apl13913-bib-0027){ref-type="ref"}, [^28^](#apl13913-bib-0028){ref-type="ref"} Our results can be regarded only as hypothesis‐generating. Physicians considering the potential value of tocilizumab in COVID‐19 in absence of robust evidence should consider whether the risk of benefit outweighs the risk of harm, particularly in view of the known roles of IL‐6 in host defense to viruses and the lack of a clear demarcation between adaptive and maladaptive inflammatory immune responses to infection. Treatment in mild or early infection could result in suppression of beneficial, antiviral effects of IL‐6‐mediated inflammation, whereas treatment too late may be ineffective.

The dose and schedule of tocilizumab used in our series varied between patients, and there is treatment heterogeneity in the published literature.[^15^](#apl13913-bib-0015){ref-type="ref"} If tocilizumab is shown to be effective for COVID‐19 CRS, phase 2 dosing studies will be required. If global supply comes under strain, the needs of both COVID and non‐COVID patients for tocilizumab will need to be considered.

In our series, the time from tocilizumab administration to an improvement in oxygenation, defined as a 25% fall in FiO2 requirement, ranged from 7 hours to 4.6 days, and radiographic improvement occurred at between 41 hours and 9.8 days. While no laboratory parameter reliably predicted clinical improvement in all five patients, changes in ferritin and lactate dehydrogenase generally correlated with clinical improvement, whereas D‐dimer, creatine kinase, troponin‐T and neutrophil counts did not. While all patients rapidly defervesced and CRP rapidly normalized, these are IL‐6‐dependent processes,[^29^](#apl13913-bib-0029){ref-type="ref"} and so are unlikely to predict clinical improvement.

This series illustrates that tocilizumab can be associated with favorable clinical outcome in some cases of severe COVID‐19 pneumonia. The Australian Society for Clinical Immunology and Allergy (ASCIA) recommends IL‐6 blockade be considered early in critically ill patients with severe COVID‐19 pneumonia.[^9^](#apl13913-bib-0009){ref-type="ref"} We concur with these recommendations and advocate for collaborative, multidisciplinary management of such patients, including judicious use of tocilizumab, while awaiting the results of large multicenter placebo‐controlled randomized trials.
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